Showing results (71-80 of 135) with videos related to

Sort By:
Pageof 14
Medical Oncology (Northwood, London, England)|May 20, 2019
Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomographyChiaki Inagaki, Tatsunori Shimoi, Hitomi Sumiyoshi Okuma, et al.
Cancer|August 6, 2014
A validated miRNA profile predicts response to therapy in esophageal adenocarcinomaHeath D Skinner, Jeffrey H Lee, Manoop S Bhutani, et al.
BMC Cancer|November 26, 2022
High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective studyShigemasa Takamizawa, Shu Yazaki, Yuki Kojima, et al.
Cancers|June 27, 2024
Immunohistochemical Profiling of SSTR2 and HIF-2α with the Tumor Microenvironment in Pheochromocytoma and ParagangliomaMasaki Uchihara, Akiyo Tanabe, Yuki Kojima, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 13, 2017
Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinomaKazuto Harada, Xiaochuan Dong, Jeannelyn S Estrella, et al.
Oncology|June 14, 2014
Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancerHironori Shiozaki, Kazuki Sudo, Lianchun Xiao, et al.
JCO Precision Oncology|May 26, 2021
Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid TumorsYuki Takeyasu, Hitomi S Okuma, Yuki Kojima, et al.
Cancer Science|September 9, 2022
First-in-human study of ONO-4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumorsSatoru Iwasa, Takafumi Koyama, Makoto Nishino, et al.
Cancer Science|March 27, 2024
Identification of barriers to implementation of precision oncology in patients with rare cancersShigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, et al.
BMC Cancer|August 9, 2022
A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trialYohei Chiba, Kazuki Sudo, Yuki Kojima, et al.
Pageof 14